WO2003076603A3 - Functionalization of t cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions - Google Patents

Functionalization of t cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions Download PDF

Info

Publication number
WO2003076603A3
WO2003076603A3 PCT/IB2003/001391 IB0301391W WO03076603A3 WO 2003076603 A3 WO2003076603 A3 WO 2003076603A3 IB 0301391 W IB0301391 W IB 0301391W WO 03076603 A3 WO03076603 A3 WO 03076603A3
Authority
WO
WIPO (PCT)
Prior art keywords
vesicles
methods
functionalization
preparation
pharmaceutical compositions
Prior art date
Application number
PCT/IB2003/001391
Other languages
French (fr)
Other versions
WO2003076603A2 (en
Inventor
Yafei Hou
Di-Hwei Hsu
Anita Mehta-Damani
Henry Lamparski
Pedro Paz
Pecq Jean-Bernard Le
Original Assignee
Anosys Inc
Yafei Hou
Di-Hwei Hsu
Anita Mehta-Damani
Henry Lamparski
Pedro Paz
Pecq Jean-Bernard Le
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anosys Inc, Yafei Hou, Di-Hwei Hsu, Anita Mehta-Damani, Henry Lamparski, Pedro Paz, Pecq Jean-Bernard Le filed Critical Anosys Inc
Priority to EP03710146A priority Critical patent/EP1483372A2/en
Priority to CA002479021A priority patent/CA2479021A1/en
Priority to US10/502,333 priority patent/US20050042272A1/en
Priority to JP2003574810A priority patent/JP2005528091A/en
Priority to AU2003214566A priority patent/AU2003214566A1/en
Publication of WO2003076603A2 publication Critical patent/WO2003076603A2/en
Publication of WO2003076603A3 publication Critical patent/WO2003076603A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C12N2500/14—Calcium; Ca chelators; Calcitonin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to compositions comprising vesicles released' from activated T lymphocytes, as well as to methods for their production and uses. Said vesicles contain a set of bioactive molecules which confer remarkable properties, such as antigen recognition, antigen presentation and other regulatory and effector functions. This invention also relates to methods for transferring or delivering antigenic molecules (e.g., peptides, peptide/MHC complexes, TCR or subunit thereof, etc.) to antigen presenting cells (APCs) using said vesicles, to induce specific immune responses, particularly specific CTL responses. The invention further relates to methods of delivering molecules selectively or specifically to target cells using said vesicles.
PCT/IB2003/001391 2002-03-14 2003-03-13 Functionalization of t cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions WO2003076603A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP03710146A EP1483372A2 (en) 2002-03-14 2003-03-13 Functionalization of t cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions
CA002479021A CA2479021A1 (en) 2002-03-14 2003-03-13 Functionalization of t cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions
US10/502,333 US20050042272A1 (en) 2002-03-14 2003-03-13 Vesiles derived from t cells, production and uses
JP2003574810A JP2005528091A (en) 2002-03-14 2003-03-13 Functionalization of T cell-derived vesicles and their use to produce immunogenic pharmaceutical compositions
AU2003214566A AU2003214566A1 (en) 2002-03-14 2003-03-13 Functionalization of T cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36384902P 2002-03-14 2002-03-14
US60/363,849 2002-03-14

Publications (2)

Publication Number Publication Date
WO2003076603A2 WO2003076603A2 (en) 2003-09-18
WO2003076603A3 true WO2003076603A3 (en) 2004-01-22

Family

ID=27805292

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/001391 WO2003076603A2 (en) 2002-03-14 2003-03-13 Functionalization of t cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions

Country Status (7)

Country Link
US (1) US20050042272A1 (en)
EP (1) EP1483372A2 (en)
JP (1) JP2005528091A (en)
CN (1) CN1639323A (en)
AU (1) AU2003214566A1 (en)
CA (1) CA2479021A1 (en)
WO (1) WO2003076603A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1417229B1 (en) 2001-08-17 2011-06-15 Exothera L.L.C. Methods and compounds for the targeting of protein to exosomes
US7914792B2 (en) 2003-02-14 2011-03-29 Exothera L.L.C. Methods and compounds for raising antibodies and for screening antibody repertoires
ES2880460T3 (en) * 2006-03-09 2021-11-24 Aethlon Medical Inc Extracorporeal removal of microvesicular particles
CN101085349B (en) * 2006-06-09 2011-05-25 项雯华 Vesicle guiding immunocyte and application of the same in preparing antineoplastic medicine
DK2094086T3 (en) * 2006-11-08 2013-11-25 Veritas Bio LLC SUBMITTING IN VIVO OF DOUBLE-STRENGTH RNA TO A TARGET CELL
CN102084000B (en) * 2008-02-01 2016-03-16 总医院有限公司 The purposes of microvesicle in the diagnosis of medical conditions and the patient's condition, prognosis and treatment
FR2928926B1 (en) * 2008-03-18 2015-08-21 Centre Nat Rech Scient CHIMERIC POLYNUCLEOTIDES AND POLYPEPTIDES FOR THE SECRETION OF A POLYPEPTIDE OF INTEREST IN ASSOCIATION WITH EXOSOMES AND THEIR USE FOR THE PRODUCTION OF IMMUNOGENIC COMPOSITIONS
KR101314868B1 (en) * 2009-07-01 2013-10-08 주식회사이언메딕스 Microvesicles derived from mammalian nucleated cell and use thereof
WO2011031892A1 (en) 2009-09-09 2011-03-17 The General Hospital Corporation Use of microvesicles in analyzing kras mutations
WO2011031877A1 (en) 2009-09-09 2011-03-17 The General Hospital Corporation Use of microvesicles in analyzing nucleic acid profiles
FR2950350B1 (en) 2009-09-24 2013-12-13 Centre Nat Rech Scient NOVEL POLYNUCLEOTIDES AND CHIMERIC POLYPEPTIDES FOR THE SECRETION OF A POLYPEPTIDE OF INTEREST IN ASSOCIATION WITH EXOSOMES AND USES THEREOF
US20120315324A1 (en) * 2010-02-05 2012-12-13 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
JP5808349B2 (en) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー Biomarkers for theranosis
JP2013526852A (en) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス Circulating biomarkers for disease
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
WO2012064993A1 (en) 2010-11-10 2012-05-18 Exosome Diagnosties, Inc. Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom
EP3888640A1 (en) 2013-06-05 2021-10-06 AgeX Therapeutics, Inc. Compositions and methods for induced tissue regeneration in mammalian species
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
AU2017205637B2 (en) * 2016-01-06 2023-01-05 Health Research, Inc. Compositions and libraries comprising recombinant T-cell receptors and methods of using recombinant T-cell receptors
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
EP3602066A1 (en) * 2017-03-21 2020-02-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the transplantation-free survival time of patients suffering from cirrhosis
WO2018183930A1 (en) * 2017-03-30 2018-10-04 Carson Dennis A Methods for isolating, expanding and administering cancer specific cd8+ t cells
CN108103026B (en) * 2017-12-05 2020-12-22 四川省肿瘤医院 Gamma-T cell exosome for tumor immunotherapy and preparation method thereof
US20240091355A1 (en) * 2019-10-11 2024-03-21 Kyungpook National University Industry-Academic Cooperation Foundation Composition, for prevention or treatment of cancer disease, comprising cytotoxic t cells activated by t helper cell-derived extracellular vesicles as active ingredient
US20210198654A1 (en) * 2019-12-26 2021-07-01 Jerome Canady Research Institute for Advanced Biological and Technological Sciences Method for isolation and harvesting microvesicles
EP3933035A1 (en) * 2020-07-03 2022-01-05 Aarhus Universitet Compositions comprising extracellular vesicles and sting stimulatory agents
CN113265378A (en) * 2021-06-16 2021-08-17 山东德升生物工程有限公司 In-vitro amplification method for killing cells by using dual mechanism of activation of cell exosomes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001082958A2 (en) * 2000-04-27 2001-11-08 Anosys, Inc. Methods of producing membrane vesicles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001082958A2 (en) * 2000-04-27 2001-11-08 Anosys, Inc. Methods of producing membrane vesicles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DENZER, K. ET AL.: "Exosome: from internal vesicle of the multivesicular body to intercellular signaling device", JOURNAL OF CELL SCIENCE, vol. 113, no. 19, October 2000 (2000-10-01), pages 3365 - 3374, XP002225014 *
MARTINEZ-LORENZO, M.J. ET AL.: "Activated Human T Cells Release Bioactive Fas Ligand and APO2 Ligand in Microvesicles", JOURNAL OF IMMUNOLOGY, vol. 163, no. 3, 1 August 1999 (1999-08-01), pages 1274 - 1281, XP002250995 *

Also Published As

Publication number Publication date
EP1483372A2 (en) 2004-12-08
AU2003214566A1 (en) 2003-09-22
WO2003076603A2 (en) 2003-09-18
CN1639323A (en) 2005-07-13
JP2005528091A (en) 2005-09-22
US20050042272A1 (en) 2005-02-24
CA2479021A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
WO2003076603A3 (en) Functionalization of t cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions
WO1999042564A3 (en) Apoptotic cell-mediated antigen presentation to dendritic cells
WO2006066214A3 (en) Use of flagellin in the immunotherapy of yersinia pestis
CA2330235A1 (en) Antigenic complex comprising immunostimulatory peptide, cd4, and chemokine receptor domain for hiv treatment and immune disorders
EP2258386A3 (en) Neisseria Vaccine composition
EP2181714A3 (en) Immunogenic composition for use in vaccination against staphylococcei
CA2245497A1 (en) Peptide immunogens for vaccination against and treatment of allergy
PT2351579T (en) Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
CN103402539A (en) A synthetic immunogen useful for generating long lasting immunity and protection against pathogens
US20100255033A1 (en) Non-toxic double mutant forms of pertussis toxin as adjuvants
WO2001072277A3 (en) Immunotherapeutic methods and compositions
CN113015541A (en) Immunogenic peptides having novel oxidoreductase motifs
AU7460896A (en) Composition and methods for enhancing immune responses mediated by antigen-presenting cells
WO2003004646A3 (en) Genetic analysis of peyers's patches and m cells and methods and compositions targeting peyer's patches and m cell receptors
RU2019113989A (en) MEDICINE
WO1999063945A3 (en) Vaccination strategy to prevent and treat cancers
WO2001068677A3 (en) Derivatives of breast canacer antigen her-2 for therapeutical use
NO875038L (en) CONJUGATED VACCINE.
EP1655305A3 (en) Therapeutic anti-cytomegalovirus compounds
CN113906046A (en) Immunogenic peptides having an oxidoreductase motif comprising a modified cysteine
CA2273922A1 (en) Novel saponin compositions and uses thereof
IL141996A0 (en) Moraxella catarrhalis basb034 polypeptides and uses thereof
WO1999047102A3 (en) Methods for enhanced antigen presentation on antigen-presenting cells and compositions produced thereby
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003710146

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003214566

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20038055333

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2479021

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003574810

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 10502333

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2003710146

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003710146

Country of ref document: EP